Skip to main content

full timeline

Psychedelic anxiety treatment clinical trials

A single-dose formulation of LSD has met its primary endpoints in a second Phase 3 clinical trial, demonstrating rapid and sustained symptom relief for patients with generalized anxiety disorder.

Factlen Newsroom· Updated

Follow Psychedelic anxiety treatment clinical trials in the Factlen app and get an alert when there is news. Get the app

The DT120 protocol involves a single supervised dosing session rather than daily medication.From: Definium Therapeutics' Single-Dose LSD Therapy Clears Second Phase 3 Trial for Generalized Anxiety Disorder

Share this story

Latest report

Definium Therapeutics' Single-Dose LSD Therapy Clears Second Phase 3 Trial for Generalized Anxiety Disorder

A single-dose formulation of LSD has met its primary endpoints in a second Phase 3 clinical trial, demonstrating rapid and sustained symptom relief for patients with generalized anxiety disorder. The results position the psychedelic compound as the first potentially new pharmacological mechanism for the condition in over two decades.

  • Definium Therapeutics' single-dose LSD therapy, DT120, cleared its second Phase 3 trial for generalized anxiety disorder.
  • The drug provided rapid and sustained symptom relief, meeting all primary clinical endpoints.
  • If approved, it would be the first new pharmacological mechanism for generalized anxiety in over 20 years.
  • The treatment previously received FDA Breakthrough Therapy designation.

On September 24, 2026, Definium Therapeutics released the topline data for its second Phase 3 clinical trial of DT120, a single-dose LSD-based therapy for generalized anxiety disorder.[5]

The readout confirmed that the compound met its primary endpoints, demonstrating a statistically significant reduction in anxiety symptoms compared to a placebo.[3][5]

This marks the second consecutive late-stage trial where the psychedelic derivative provided rapid and sustained relief after just one administered dose, giving the drug a 3-for-3 success rate across its recent major clinical tests.[1][2]

Generalized anxiety disorder affects an estimated 6.8 million adults in the United States annually, yet the condition has not seen a fundamentally new class of pharmacological treatment approved in more than two decades.[1]

Definium Therapeutics is testing the LSD-based compound as a single-dose treatment.

Current standard-of-care medications, primarily selective serotonin reuptake inhibitors, typically require daily dosing and take between four to six weeks to reach therapeutic efficacy.[1][4]

In contrast, the DT120 protocol involves a single supervised dosing session, after which patients in the trial reported sustained reductions in baseline anxiety metrics without the need for daily medication.[2][5]

The financial markets reacted to the clinical milestone on September 25, with analysts noting that the positive data could shift the narrative around Definium Therapeutics as it prepares for potential regulatory filings.[4]

The company is also evaluating the compound for other indications, recently highlighting parallel Phase 3 data for DT120 in treating major depressive disorder.[5][6]

The compound met its primary endpoints in its second Phase 3 trial.

The FDA previously granted Breakthrough Therapy designation to the treatment in 2024, an expedited pathway reserved for drugs that show substantial improvement over available therapies for serious conditions.[2]

The initial data releases from the company did not include direct quotations from the principal investigators, but the published readouts confirmed the primary endpoints were achieved across the study cohorts.[3][5]

The next step for Definium Therapeutics will be compiling the comprehensive data package from these Phase 3 trials to submit a New Drug Application to the FDA for commercial approval.[4][5]

Sources

  1. [1]Health and Me — LSD-Based Treatment Clears Second Phase 3 Trial: Could It Be The First New GAD Drug In 2 Decades? Read on Health and Me →
  2. [2]Biotech Morning — An LSD Pill Just Went 3-for-3 in the Biggest Test of Psychedelic Medicine Read on Biotech Morning →
  3. [3]The Pharmaletter — Definium reports third positive Phase III readout for LSD anxiety drug Read on The Pharmaletter →
  4. [4]Simply Wall St. — Will Positive Phase 3 Anxiety Data Change Definium Therapeutics' (DFTX) Narrative Read on Simply Wall St. →
  5. [5]MarketBeat — Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression Read on MarketBeat →
  6. [6]Healthesystems — Emerging Therapies: Phase 3 Data for LSD-Based Drug in Major Depression Read on Healthesystems →

Key numbers

Patients achieving clinical remission at week 4
62%
Median time to significant symptom reduction
14 days
Reported cases of hallucinogenic side effects
0
Participants in the Phase 3 trial
412

From: Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder

Charts, maps and images

Key efficacy and safety metrics from the 412-patient Phase 3 trial.From: Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder ·
Patients receiving DT120 saw significant symptom reduction within the first two weeks of treatment.From: Phase 3 Trial Shows Psychedelic-Derived DT120 Achieves Rapid Remission for Generalized Anxiety Disorder ·